Nasdaq · CIK 0001035354
ELOX Eloxx Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Jun 10, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
4
with a Form 4 at this company
Signals
Open-market buys and sells at Eloxx Pharmaceuticals, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 33 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +328,833 | $0.00 | $0 | 328,833 | Jun 10, 2026 |
| Aug 14, 2025 | Sumit Aggarwal President and CEO | MOption exercise Common Stock | +196,880 | $0.00 | $20 | 396,810 | May 8, 2026 |
| Sep 19, 2025 | Sumit Aggarwal President and CEO | AGrant or award Common Stock | +1,000,000 | $0.00 | $0 | 1,396,810 | May 8, 2026 |
| Jan 24, 2026 | Sumit Aggarwal President and CEO | MOption exercise Common Stock | +15,000 | - | - | 1,411,810 | May 8, 2026 |
| Feb 28, 2026 | Sumit Aggarwal President and CEO | MOption exercise Common Stock | +260,946 | $0.15 | $39k | 1,672,756 | May 8, 2026 |
| Feb 6, 2022 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +42,790 | $0.00 | $0 | 42,790 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -42,790 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +42,790 | - | - | 42,790 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -35,580 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +35,580 | - | - | 35,580 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -24,810 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +24,810 | - | - | 24,810 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | DDisposition to issuer Stock Option (Right to Buy)derivative | -68,700 | - | - | 0 | May 8, 2026 |
| Oct 16, 2024 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +68,700 | - | - | 68,700 | May 8, 2026 |
| Aug 14, 2025 | Sumit Aggarwal President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -60,390 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | Sumit Aggarwal President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -68,700 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | Sumit Aggarwal President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | May 8, 2026 |
| Aug 14, 2025 | Sumit Aggarwal President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -42,790 | $0.00 | $0 | 0 | May 8, 2026 |
| Sep 19, 2025 | Sumit Aggarwal President and CEO | AGrant or award Stock Option (Right to Buy)derivative | +3,597,090 | $0.00 | $0 | 3,597,090 | May 8, 2026 |
| Jan 24, 2026 | Sumit Aggarwal President and CEO | MOption exercise Restricted Stock Unitsderivative | -15,000 | $0.00 | $0 | 15,000 | May 8, 2026 |
| Feb 28, 2026 | Sumit Aggarwal President and CEO | MOption exercise Stock Option (Right to Buy)derivative | -260,946 | $0.00 | $0 | 3,336,144 | May 8, 2026 |
| Jan 24, 2025 | Steven D Rubin director | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 15,750 | Jan 28, 2025 |
| Jan 24, 2025 | Alan Edmund Walts director | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 16,692 | Jan 28, 2025 |
| Jan 24, 2025 | Lindsay Androski director | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 15,750 | Jan 28, 2025 |
| Jan 24, 2025 | Sumit Aggarwal President and CEO | MOption exercise Common Stock | +30,000 | $0.00 | $0 | 199,930 | Jan 28, 2025 |
| Jan 24, 2025 | Steven D Rubin director | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 3,750 | Jan 28, 2025 |
| Jan 24, 2025 | Alan Edmund Walts director | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 3,750 | Jan 28, 2025 |
| Jan 24, 2025 | Lindsay Androski director | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 3,750 | Jan 28, 2025 |
| Jan 24, 2025 | Sumit Aggarwal President and CEO | MOption exercise Restricted Stock Unitsderivative | -30,000 | $0.00 | $0 | 30,000 | Jan 28, 2025 |
| Oct 16, 2024 | Lindsay Androski director | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 12,000 | Oct 17, 2024 |
| Oct 16, 2024 | Steven D Rubin director | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 12,000 | Oct 17, 2024 |
| Oct 16, 2024 | Alan Edmund Walts director | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 12,942 | Oct 17, 2024 |
| Oct 16, 2024 | Sumit Aggarwal PRESIDENT AND CEO | AGrant or award Common Stock | +165,000 | $0.00 | $0 | 169,930 | Oct 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Sumit AggarwalPresident and CEO
- Lindsay Androskidirector, ceo, president, officer
- Steven D Rubindirector, officer
- Alan Edmund Waltsdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.